Oncology Drug Reference Sheet: Blinatumomab

Kristine B. LeFebvre MSN, RN, AOCN®


Blinatumomab received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2014 for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL). The drug’s unique administration procedures have prompted nurses to evaluate their practice for safety.

View Article @ voice.ons.org

ONS Articles

Dive into a rich source of oncology nursing expertise with ONS articles.

View All Articles

Related Topics